Education
About Us
Working with TipRanks
Follow Us
BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
BMRN Stock Chart & Stats
$54.73
$0.93(1.37%)
At close: 4:00 PM EST
$54.73
$0.93(1.37%)
Day’s Range― - ―
52-Week Range$50.76 - $73.51
Previous CloseN/A
Volume465.01K
Average Volume (3M)2.61M
Market Cap
$10.51B
Enterprise Value$9.53B
Total Cash (Recent Filing)$1.48B
Total Debt (Recent Filing)$596.66M
Price to Earnings (P/E)20.5
Beta0.49
Next Earnings
Feb 25, 2026EPS Estimate
0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding192,114,350
10 Day Avg. Volume2,355,691
30 Day Avg. Volume2,614,269
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)2.21
Price to Sales (P/S)4.38
P/FCF Ratio26.27
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue3.08
Enterprise Value/Gross Profit3.79
Enterprise Value/Ebitda12.34
Forecast
1Y Price Target
$87.50Price Target Upside59.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)2.8
Revenue Forecast (FY)$3.17B
Bulls Say, Bears Say
Bulls Say
Pipeline DevelopmentsBioMarin's pipeline remains active, with '333 advancing toward a Phase II/III registrational trial in achondroplasia and pivotal data for Voxzogo in hypochondroplasia expected.
Regulatory ApprovalThe FDA has accepted the supplemental Biologics License Application (sBLA) for Palynziq, which seeks to expand its use to phenylketonuria (PKU) patients age 12 to 17 years with priority review.
Revenue GuidanceManagement reaffirmed Vozogo FY25 guidance and implied an increase in revenues to the base business by raising the bottom of their revenue by $25M.
Bears Say
Competitive PressureThe recent commercialization of PTC Therapeutics’ Sephience could limit initial uptake in the adolescent patient population.
Guidance WithdrawalManagement withdrew the $4bn 2027 revenue guidance, noting it was likely too high before seeing competitor data.
Revenue MissBMRN reported a topline miss for 3Q with Voxzogo coming in light versus estimates and down slightly quarter-over-quarter.
BioMarin Pharmaceutical News
BMRN FAQ
What was BioMarin Pharmaceutical’s price range in the past 12 months?
BioMarin Pharmaceutical lowest stock price was $50.76 and its highest was $73.51 in the past 12 months.
What is BioMarin Pharmaceutical’s market cap?
BioMarin Pharmaceutical’s market cap is $10.51B.
When is BioMarin Pharmaceutical’s upcoming earnings report date?
BioMarin Pharmaceutical’s upcoming earnings report date is Feb 25, 2026 which is in 100 days.
How were BioMarin Pharmaceutical’s earnings last quarter?
BioMarin Pharmaceutical released its earnings results on Oct 27, 2025. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.265 by $0.105.
Is BioMarin Pharmaceutical overvalued?
According to Wall Street analysts BioMarin Pharmaceutical’s price is currently Undervalued.
Does BioMarin Pharmaceutical pay dividends?
BioMarin Pharmaceutical does not currently pay dividends.
What is BioMarin Pharmaceutical’s EPS estimate?
BioMarin Pharmaceutical’s EPS estimate is 0.81.
How many shares outstanding does BioMarin Pharmaceutical have?
BioMarin Pharmaceutical has 192,114,350 shares outstanding.
What happened to BioMarin Pharmaceutical’s price movement after its last earnings report?
BioMarin Pharmaceutical reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.265. Following the earnings report the stock price went up 1.557%.
Which hedge fund is a major shareholder of BioMarin Pharmaceutical?
Currently, no hedge funds are holding shares in BMRN
BioMarin Pharmaceutical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$87.50 (59.88% Upside)
$87.50 (59.88% Upside)
Blogger Sentiment
Bullish
BMRN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 5.2%
Last 30 Days ▲ 5.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.57%
12-Months-Change
Fundamentals
Return on Equity
9.07%
Trailing 12-Months
Asset Growth
11.15%
Trailing 12-Months
Company Description
BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
BMRN Company Deck
BMRN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted BioMarin's strong revenue growth, particularly with VOXZOGO and enzyme therapies, alongside a solid cash position and operational efficiency. However, challenges included a significant IPR&D charge, the decision to divest ROCTAVIAN, and enzyme therapy revenue fluctuations. While there are notable achievements, the presence of significant lowlights balances the overall sentiment.View all BMRN earnings summariesBMRN Revenue Breakdown
28.98% VIMIZIM
19.42% VOXZOGO
17.37% NAGLAZYME
12.56% PALYNZIQ
21.66% Other
BMRN Stock 12 Month Forecast
Average Price Target
$87.50
▲(59.88% Upside)
Technical Analysis
Ownership Overview
0.45% Insiders
30.55% Mutual Funds
27.10% Other Institutional Investors
19.35% Public Companies and Individual Investors